SWK Holdings Corp (NAS:SWKH)

$ 16.03 -0.23 (-1.41%) Market Cap: 196.10 Mil Enterprise Value: 212.98 Mil PE Ratio: 17.24 PB Ratio: 0.69 GF Score: 71/100

Q2 2024 SWK Holdings Corp Earnings Call Transcript
Aug 16, 2024

$17.33 (+2.30%)

Earnings
Q1 2024 SWK Holdings Corp Earnings Call Transcript
May 16, 2024

$17.36 (-1.64%)

Earnings
Q3 2023 SWK Holdings Corp Earnings Call Transcript
Nov 09, 2023

$16.01 (-2.26%)

Earnings
Q2 2023 SWK Holdings Corp Earnings Call Transcript
Aug 09, 2023

$16.08 (+2.42%)

Earnings
SWK Holdings Corp Annual Shareholders Meeting Transcript
Jun 14, 2023
Q1 2023 SWK Holdings Corp Earnings Call Transcript
May 11, 2023

$17.21 (+0.17%)

Earnings
Q4 2022 SWK Holdings Corp Earnings Call Transcript
Apr 03, 2023

$17.41 (-2.52%)

Earnings
Q3 2022 SWK Holdings Corp Earnings Call Transcript
Nov 10, 2022

$19.37 (+1.68%)

Earnings
Q2 2022 SWK Holdings Corp Earnings Call Transcript
Aug 11, 2022

$17.82 (-4.86%)

Earnings
Q1 2022 SWK Holdings Corp Earnings Call Transcript
May 11, 2022

$19.3 (+0.84%)

Earnings
Q4 2021 SWK Holdings Corp Earnings Call Transcript
Mar 28, 2022

$17.81 (-2.73%)

Earnings
Q3 2021 SWK Holdings Corp Earnings Call Transcript
Nov 15, 2021

$18.61 (-0.48%)

Earnings
Q2 2021 SWK Holdings Corp Earnings Call Transcript
Aug 17, 2021

$17.78 (+2.95%)

Earnings
Q4 2020 SWK Holdings Corp Earnings Call Transcript
Apr 01, 2021

$15.2 (+4.54%)

Earnings
Q2 2020 SWK Holdings Corp Earnings Call Transcript
Aug 17, 2020

$13 (+4.50%)

Earnings
Q4 2019 SWK Holdings Corp Earnings Call Transcript
Mar 31, 2020

$11.2 (+0.54%)

Earnings
SWK Holdings Corp Corporate Analyst Meeting Transcript
Jan 30, 2020
SWK Holdings Corp Acquires Enteris BioPharma Inc - M&A Call Transcript
Aug 27, 2019

SWK Holdings Corp Acquires Enteris BioPharma Inc - M&A Call Transcript

Aug 27, 2019 / 03:00PM GMT

Release Date Price: $10.35 (+1.97%)

Transcript

Operator

Good morning and welcome to the SWK Holdings Corporation Acquires Enteris BioPharma conference call. (Operator Instructions). Please note this event is being recorded. I would now like to turn the conference over to Jason Rando of Tiberend Strategic Advisors. Please go ahead.

Jason Rando

Tiberend Strategic Advisors, Inc. - IR

Good morning everyone and thank you for joining us to discuss SWK Holdings' strategic acquisition of Enteris BioPharma. Earlier this morning the two companies issued a press release detailing the acquisition, which we encourage listeners to read. The press release can be found in the News sections of SWKHold.com and EnterisBioPharma.com. SWK Holdings also filed an 8-K this morning, which is available on SWKHold.com and SEC.gov.

Before beginning today's call, I would like to make the following statement regarding forward-looking statements. Today we'll be making forward-looking statements about future expectations, plans, events and circumstances, including statements about our strategy, future operations and the development of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.